HEALIUS (AU), a company active in the Health Care Providers industry, sees its general evaluation downgraded to Neutral on account of a double requalification. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour has also deteriorated and is evaluated as moderately risky. theScreener believes that the loss of a star(s) and the increased risk justifies the general evaluation downgrade, which passes to Neutral. As of...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
After rallying approximately 35% since the beginning of calendar 2019, shares in Healius are now modestly undervalued relative to our unchanged AUD 3.50 fair value estimate. Major shareholder Jangho's takeover bid in early January 2019 was opportunistic, and the subsequent rejection by the board reflected our opinion that the AUD 3.25 bid undervalued the firm. Healius' large-scale medical centres generate dependable earnings, and its pathology division in particular enjoys competitive advantages...
Healius provides investors with exposure to a portfolio of medical businesses with reliable earning streams. We expect the latter to grow solidly over the medium and longer term as the firm fills excess capacity and benefits from rising demand from an aging population. Earnings should be relatively insulated from cuts to public healthcare budgets, as the effective delivery of diagnostic services helps to constrain healthcare costs by enabling early treatment of disease. The aging population and ...
After rallying approximately 35% since the beginning of calendar 2019, shares in Healius are now modestly undervalued relative to our unchanged AUD 3.50 fair value estimate. Major shareholder Jangho's takeover bid in early January 2019 was opportunistic, and the subsequent rejection by the board reflected our opinion that the AUD 3.25 bid undervalued the firm. Healius' large-scale medical centres generate dependable earnings, and its pathology division in particular enjoys competitive advantages...
No-moat Healius reported underlying net profit after taxes of AUD 39 million for the first half of fiscal 2019, down 10% from the prior corresponding period. The weak performance reflected soft market conditions across all divisions, mostly driven by the benign winter flu season. However, we do not expect these conditions to continue and expect volumes to eventually revert toward the historical norm. The second half of fiscal 2019 should improve, as efficiency initiatives in pathology and imagin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.